Surveillance Plan

The regulatory approval process is exhausting. The temptation, once you finally have clearance, is to exhale and move on to the next project. But the reality is your device's most important phase is just beginning. Medical device recalls reached a four-year high in 2024, with more than 10% classified as the most serious type. That is over 1,000 recall events in a single year, a 25% increase from the previous year. The pattern is not improving. Early 2025 data shows Class I recalls (those with a reasonable chance of causing serious harm or death) running even higher.

These are not rogue manufacturers cutting corners. Many are established companies whose devices have passed rigorous pre-market testing. The difference between success and recall often comes down to one thing: post-market surveillance.

Beyond the complaint box

Most companies treat post-market surveillance as complaint management. A customer calls, someone logs the issue, and the quality team investigates if the numbers warrant it. This approach is not wrong. It is simply insufficient. The EU MDR and the UK's new post-market surveillance regulations both require a more comprehensive approach. They demand that manufacturers gather data, not passively wait for it to be gathered.

Social media monitoring is no longer optional. Patients discuss their experiences on forums, Facebook groups, and Twitter threads long before they file formal complaints. A negative trend on social media can signal a problem months before it appears in your official data. Ignoring these channels is like monitoring half the conversation.

The collection of real-world data helps manufacturers to further improve the safety and performance of their devices.

_{Laura Squire. MedTech Regulatory Reform Lead and Chief Officer. MHRA}

The aim ‘to further improve’ signals a shift from surveillance as defensive compliance to surveillance as a competitive advantage.

Setting clear triggers

When does a complaint become a crisis? When does a pattern become a problem? Without predefined thresholds, these questions become matters of opinion rather than protocol. Your surveillance plan needs to include specific triggers for escalation. While a 10% increase in a particular complaint type can warrant investigation, three similar adverse events within a month can require root cause analysis, but two serious injuries? This can demand immediate corrective action.

These thresholds don’t need to be arbitrary. They should reflect the risk profile of your device, the severity of potential harms, and the regulatory expectations of your target markets. Define them before you launch, not after something goes wrong. The UK's new regulations require manufacturers to report any statistically significant increase in the frequency or severity of incidents. That means you need baseline data, trend analysis, and systems capable of detecting meaningful deviations from normal patterns.

Global data, local relevance

If your device sells in multiple markets, your surveillance plan needs to account for all of them. While patient populations differ, usage patterns will vary. Healthcare systems create different contexts for device performance, and a complication rate that appears acceptable in aggregate might mask a significant problem in one specific market. Regional data collection is not bureaucratic duplication; it’s essential epidemiology.

The MHRA expects UK-specific data to be clearly identifiable within surveillance reports. The EU MDR requires similar specificity. Manufacturers who treat surveillance as a single global exercise will find their documentation rejected by regulators who need granular, market-level insights.

A future-fit legal framework needs to be efficient, predictable, and innovation-friendly. One that ensures patient safety, while enabling timely access to technologies across Europe.

_{Petra Zoellner, Director of Regulatory Affairs at MedTech Europe}

Efficient regulation depends on efficient data. The quality of your surveillance directly affects how quickly regulators can evaluate your device's ongoing safety profile.

Feeding insights back into design

Here’s where surveillance transforms from obligation to opportunity. Every complaint, every adverse event, every unexpected use case contains information about how your device performs in the real world. This information is gold. It will tell you things clinical trials never could, because clinical trials operate in controlled conditions with selected patients and trained users.

So, create a formal process to channel post-market insights back into your design and development teams. A recurring user error might indicate a design flaw that human factors engineering can address. A pattern of failures in specific conditions might reveal a durability issue. An unexpected clinical application might suggest a label expansion opportunity.

Companies that treat surveillance data as compliance documentation are missing half the value. Companies that treat it as product intelligence gain continuous improvement capability.

The proactive mindset

While reactive surveillance will ask what went wrong, proactive surveillance asks what might go wrong and how we can detect it early. For novel technologies, innovative devices, and products entering new markets, active monitoring programmes are essential. You should plan for post-market clinical follow-up studies, establish registries where feasible, and engage healthcare professionals in structured feedback programmes.

The MHRA encourages manufacturers to continue gathering data long after the validated device lifetime, throughout the period when a device might reasonably remain in use. Unexpected late-emerging risks need to be detected as quickly as possible.

This is where all that documentation comes to the fore

Your surveillance plan is not a once-and-done document. It requires regular review and alignment with your actual surveillance activities. Regulators expect to see evidence that your plan is being implemented and that insights are being acted upon. The UK's new regulations allow the MHRA to request a post-market surveillance report at any time, with a three-working-day turnaround. Your documentation must be current, accurate, and readily accessible.

VP Ventures Workshop

Post-market surveillance is where regulatory promise meets clinical reality. Done well, it protects patients, protects your reputation, and drives continuous improvement. A workshop with VP Med Ventures can be the difference between success and recall with a post-market surveillance plan. Your device's life begins at launch. So let’s make sure you’re watching.

Waypoint checklist

A considered reminder with your surveillance plan:

• Look beyond complaints by actively gathering data from sources like social media.
• Set clear triggers for investigating issues by defining specific thresholds for a rise in complaints or adverse events requires a formal investigation.
• Include data collection from all markets to ensure your plan covers gathering and analysing post-market data from every country where your device is sold.
• Use feedback to improve the product design by creating a process to feed insights from post-market data directly back into your design and development efforts.
• Use the information you collect after your device is launched to make it even better, not just to report problems.